Senseonics Reports Record Q2 2026 Revenue, Raises Full-Year Guidance on Surging Eversense CGM Demand
核心洞察
Senseonics reported Q2 2026 revenue of $14.5 million, a 120% year-over-year increase, marking the strongest quarter in company history.
U.S. revenue grew more than 150% year-over-year, driven by direct-to-consumer marketing now representing 60% of new patient acquisition.
The company raised full-year 2026 revenue guidance to $62–$66 million and gross margin guidance to 58%–61%.
Senseonics Holdings, Inc. (搜索) (NASDAQ: SENS) delivered the strongest quarter in its history, reporting second-quarter 2026 revenue of $14.5 million — an increase of approximately 120% compared to $6.6 million in the same period last year. The medical technology company, which specializes in long-term implantable continuous glucose monitoring (CGM) systems, also raised its full-year revenue and gross margin guidance, reflecting sustained commercial momentum following its decision to bring global commercial operations fully in-house.
"This was the strongest quarter in Senseonics' history, achieving record revenue and expanded margins, while integrating European commercial operations, building Eon Care, and advancing our Gemini and Freedom development programs," said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. "Revenue grew approximately 120% year-over-year, and we delivered gross margin above our guided range for the second consecutive quarter, which validates the decision we made to bring our commercial organization fully in-house."
U.S. Commercial Momentum Accelerates
U.S. revenue reached $12.6 million for the second quarter of 2026, representing growth of more than 150% compared to $4.9 million in the prior-year period. The company achieved its highest quarterly shipment volume on record, with active prescribers up approximately 130% year-over-year.
Direct-to-consumer (DTC) marketing has emerged as the dominant driver of patient acquisition, now accounting for 60% of new business. The company reported 100%+ growth in DTC patients and 40% growth in healthcare providers (HCPs) during the first quarter, with prescribers up 80% year-on-year. Senseonics has deployed targeted, geo-fenced campaigns with high-quality lead generation to fuel this expansion.
"Our commercial momentum continues to build, with strong U.S. direct-to-consumer results, now representing our largest source of new patients, improved productivity across our health care provider channel, and continued expansion of Eon Care," said Brian Hansen, Chief Commercial Officer of Senseonics.
Eon Care Network Scales Toward Year-End Target
The company's Eon nurse network has expanded past 90 nurses and now supports approximately 40% of Eversense insertion procedures, on track toward the year-end goal of 100 nurses. This network, which began at around 80 nurses, has been instrumental in improving patient access and clinic penetration for the implantable CGM system.
European Integration Completed
Senseonics closed the commercial transition of its European business from Ascensia (搜索) in June, bringing the full sales and marketing organization in-house across Germany, Italy, Spain, and Sweden. Revenue outside the U.S. was $1.9 million compared to $1.7 million in the prior-year period, an increase of approximately 12%. The company noted that this reflected the timing of tender updates in Europe and expects normalization in the third and fourth quarters, with Europe still anticipated to represent approximately 20% of full-year revenue.
Real-World Performance and twiist Pump Integration
Eversense 365 (搜索) demonstrated strong real-world performance metrics, with high transmitter wear time ranging from 93% to 99% and stable glucose metrics sustained over a full year. Patients achieved a mean glucose of 160 mg/dL and a glucose management indicator (GMI) of 7.14% in open-loop settings, with time-in-range at 66%.
Notably, integration with the twiist Automated Insulin Delivery system (搜索) produced what the company described as best-in-class outcomes: median transmitter wear time of 99%, average glucose of 144 mg/dL, GMI of 6.76%, and time-in-range reaching 76.6%. Case studies highlighted improved glycemic control, reduced hypoglycemia, and high patient satisfaction, particularly among those with prior sensor issues.
Financial Results and Strengthened Balance Sheet
Second-quarter 2026 gross profit reached $8.6 million, representing a gross margin of approximately 59%, compared to $3.1 million (47% gross margin) in the second quarter of 2025. Research and development expenses increased to $11.6 million from $7.7 million, reflecting Gemini clinical activities and ongoing Freedom development. Selling, general and administrative expenses rose to $32.9 million from $9.7 million, primarily related to the commercial integration and European transition.
Net loss for the quarter was $36.7 million, or $0.63 per share, compared to a net loss of $14.5 million, or $0.36 per share, in the prior-year period.
The company strengthened its balance sheet with more than $100 million raised during the second quarter — approximately $90 million in equity proceeds plus an expanded Hercules Capital facility of up to $140 million. As of June 30, 2026, cash, restricted cash, and cash equivalents totaled $143.0 million, with outstanding indebtedness of $55.5 million.
Raised 2026 Outlook
Senseonics raised its full-year 2026 global net revenue guidance to $62 million to $66 million, up from the prior range of $60 million to $64 million, representing year-over-year growth of 76% to 87%. The company also raised its full-year gross margin guidance to a range of 58% to 61%, up from 55% to 58%. The outlook reflects the ongoing roll-out of Eversense 365 (搜索) outside the United States, planned DTC marketing investment, and utilization of patient assistance programs.
"Given our momentum, we're raising our full-year revenue and margin guidance. We're not just growing the business — we're redefining what a CGM can be," Goodnow said.